Skip to main content
Premium Trial:

Request an Annual Quote

GE to Acquire Amersham in 5.7B Stock Deal: Amersham Life Science Business To Be Combined with GE Medical

NEW YORK, Oct. 10 (GenomeWeb News) -   General Electric has made a successful bid to acquire Amersham PLC in an £5.7 billion ($9.5 billion) all-stock deal, subject to the waiver of some "regulatory pre-conditions," the companies said early today.

 

Statements by GE executives indicate that the company plans to retain Amersham's life sciences business in the acquisition. GE Healthcare Technologies, to be based in the UK, will combine Amersham and GE Medical, the companies said.

 

"Amersham's diagnostic pharmaceutical and life sciences business will add new, high growth platforms to GE Medical's diagnostic imaging, services and healthcare information technology businesses," Jeffrey Immelt, chairman and CEO of GE said in a statement. "The combination of this technological and market knowledge will allow GE to accelerate the development of molecular imaging and personalised medicine where it will be possible to predict and treat disease with therapies tailored to the individual."

 

When the acquisition is complete, Sir William Castell, chairman of Amersham, will become a vice chairman of GE  as well as CEO of GE Healthcare Technologies, and will Join GE's board. However, Joseph Hogan, who is a senior vice president of GE and leader of GE Medical, will continue in this position, the companies said.

 

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.